SOON Stock Analysis: Sonova H | SW
Medical Devices | SW, Switzerland | Market Cap: 14.863m CHF | 12M Return: 22% | CH0012549785 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 27.3M
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sonova Holding AG is a Swiss manufacturer of hearing care solutions, operating globally with three business segments: Hearing Instruments (its core business, offering hearing aids and related products under brands such as Phonak, Unitron, Hansaton, and Sennheiser), Cochlear Implants (under Advanced Bionics), and Lifestyle-Aligned (focused on connected solutions with AI and digital capabilities). The company distributes its products through a mix of channels, including its own retail store network, wholesale to independent audiologists and third-party retailers, and sales to government and institutional customers, while also providing audiological care services through brands such as AudioNova, Connect Hearing, and Boots Hearingcare. Headquartered in Stäfa and founded in 1947, Sonova was originally known as Phonak Holding AG before adopting its current name in 2007.
Sonova operates in the Health Care Equipment sub-industry, a sector whose demand is structurally supported by aging populations in developed markets and rising hearing-loss awareness globally. The global hearing aid industry is highly consolidated, with a small group of large manufacturers accounting for the majority of unit sales, which underscores the importance of brand portfolios and direct retail networks like Sonovas.
- US OTC hearing aid regulation pressures premium pricing
- Cochlear implants margin recovery supports profit growth
- Strong Swiss franc weighs on reported revenue growth
| Net Income: 430.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -0.37 > 1.0 |
| NWC/Revenue: 24.82% < 20% (prev 14.43%; Δ 10.39% < -1%) |
| CFO/TA 0.12 > 3% & CFO 684.1m > Net Income 430.6m |
| Net Debt (1.23b) to EBITDA (841.5m): 1.46 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.4m) vs 12m ago 1.02% < -2% |
| Gross Margin: 73.72% > 18% (prev 72.03%; Δ 1.69% > 0.5%) |
| Asset Turnover: 62.42% > 50% (prev 48.10%; Δ 14.33% > 0%) |
| Interest Coverage Ratio: 8.05 > 6 (EBIT TTM 704.8m / Interest Expense TTM 87.6m) |
| A: 0.16 (Total Current Assets 2.08b - Total Current Liabilities 1.19b) / Total Assets 5.63b |
| B: 0.63 (Retained Earnings 3.52b / Total Assets 5.63b) |
| C: 0.12 (EBIT TTM 704.8m / Avg Total Assets 5.78b) |
| D: 0.87 (Book Value of Equity 2.61b / Total Liabilities 2.99b) |
| Altman-Z'' = 4.82 = AA |
| DSRI: 0.77 (Receivables 665.1m/681.1m, Revenue 3.61b/2.85b) |
| GMI: 0.98 (GM 72.03% / 73.72%) |
| AQI: 0.92 (AQ_t 0.52 / AQ_t-1 0.57) |
| SGI: 1.27 (Revenue 3.61b / 2.85b) |
| TATA: -0.05 (NI 430.6m - CFO 684.1m) / TA 5.63b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at CHF 264.60 with a total of 151,903 shares traded. Over the past week, the price has changed by +6.52%, over one month by +16.36%, over three months by +30.86% and over the past year by +21.95%.
Current recommended Stop Loss: 258.80 (which is 2.2% or 1.3 ATR below the current price).
Sonova H has no consensus analysts rating.
P/E Trailing = 27.7691
P/E Forward = 21.097
P/S = 4.1219
P/B = 5.4998
P/EG = 1.3519
Revenue TTM = 3.61b CHF
EBIT TTM = 704.8m CHF
EBITDA TTM = 841.5m CHF
Long Term Debt = 1.35b CHF (from longTermDebt, last quarter)
Short Term Debt = 186.3m CHF (from shortTermDebt, last quarter)
Debt = 1.95b CHF (from shortLongTermDebtTotal, last quarter) + Leases 240.9m
Net Debt = 1.23b CHF (calculated: Debt 1.95b - CCE 722.1m)
Enterprise Value = 16.1b CHF (14.9b + Debt 1.95b - CCE 722.1m)
Interest Coverage Ratio = 8.05 (Ebit TTM 704.8m / Interest Expense TTM 87.6m)
EV/FCF = 26.70x (Enterprise Value 16.1b / FCF TTM 602.7m)
FCF Yield = 3.74% (FCF TTM 602.7m / Enterprise Value 16.1b)
FCF Margin = 16.71% (FCF TTM 602.7m / Revenue TTM 3.61b)
Net Margin = 11.94% (Net Income TTM 430.6m / Revenue TTM 3.61b)
Gross Margin = 73.72% ((Revenue TTM 3.61b - Cost of Revenue TTM 947.6m) / Revenue TTM)
Gross Margin QoQ = 77.20% (prev 70.29%)
Tobins Q-Ratio = 2.86 (Enterprise Value 16.1b / Total Assets 5.63b)
Interest Expense / Debt = 4.49% (Interest Expense 87.6m / Debt 1.95b)
Taxrate = 14.92% (95.7m / 641.6m)
NOPAT = 599.7m (EBIT 704.8m * (1 - 14.92%))
Current Ratio = 1.75 (Total Current Assets 2.08b / Total Current Liabilities 1.19b)
Debt / Equity = 0.75 (Debt 1.95b / totalStockholderEquity, last quarter 2.61b)
Debt / EBITDA = 1.46 (Net Debt 1.23b / EBITDA 841.5m)
Debt / FCF = 2.04 (Net Debt 1.23b / FCF TTM 602.7m)
Total Stockholder Equity = 2.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.45% (Net Income 430.6m / Total Assets 5.63b)
RoE = 17.23% (Net Income TTM 430.6m / Total Stockholder Equity 2.50b)
RoCE = 18.30% (EBIT 704.8m / Capital Employed (Equity 2.50b + L.T.Debt 1.35b))
RoIC = 13.49% (NOPAT 599.7m / Invested Capital 4.45b)
WACC = 7.59% (E(14.9b)/V(16.8b) * Re(8.08%) + D(1.95b)/V(16.8b) * Rd(4.49%) * (1-Tc(0.15)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -69.52 | Cagr: -1.67%
[DCF] Terminal Value 74.26% ; FCFF base≈624.1m ; Y1≈583.8m ; Y5≈536.9m
[DCF] Fair Price = 122.1 (EV 8.48b - Net Debt 1.23b = Equity 7.25b / Shares 59.4m; r=8.35% [WACC [floored]]; 5y FCF grow -8.14% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: -43.81 | Revenue CAGR: -5.87% | SUE: -0.13 | # QB: 0
EPS current Year (2026-03-31): EPS=9.52 | Chg30d=-1.83% | Revisions=-29% | GrowthEPS=-12.0% | GrowthRev=-3.4%
EPS next Year (2027-03-31): EPS=10.81 | Chg30d=+1.16% | Revisions=+50% | GrowthEPS=+1.4% | GrowthRev=+6.7%
[Analyst] Revisions Ratio: +10% (up=4, down=3)